Bedrijfsoverzicht
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise that specializes in the three-dimensional bioprinting of tissues and organs, alongside offering medical aesthetics solutions across the United States, Canada, Israel, Europe, and international markets. The company operates within the Healthcare sector, specifically the Biotechnology industry, which implies a focus on developing biological products and therapies to address unmet medical needs through advanced scientific research and development. As of the latest available data, the company holds a market capitalization of $5.51 million, generates annual revenue of $2.37 million, and employs a workforce of 39 individuals. These financial and operational metrics indicate that CollPlant Biotechnologies functions as a small-cap entity with a limited revenue base relative to its market capitalization, suggesting it is in an early-stage development phase where capital allocation is heavily weighted toward research and operational scaling rather than mature profit generation.
Financiële gezondheid
The company reported a total revenue of $2.37 million over the trailing twelve months, while simultaneously posting a net income loss of $11,489,000 and an EBITDA loss of $10,571,000. The substantial negative gap between the positive revenue of $2.37 million and the significant net income loss reveals a cost structure characterized by high operating expenses, likely driven by research and development costs typical for biotechnology firms that have not yet achieved commercial profitability. Free cash flow stands at -$5,480,875, indicating that the company is currently burning cash, which limits its immediate financial flexibility and necessitates reliance on external financing or existing cash reserves to fund ongoing operations. Analyzing the margin profile, the gross margin is recorded at 64.8%, suggesting a relatively efficient production or cost-of-goods-sold structure for its core products; however, the operating margin is an extreme negative figure of -5250.0%, and the profit margin is 0.0%, highlighting that overhead costs and R&D expenditures are so high that they completely negate gross profitability at this stage. The balance sheet shows a cash position of $5.59 million against total debt of $2.85 million, resulting in a debt-to-equity ratio of 46.80, which suggests a leveraged capital structure where equity is the primary funding source despite the presence of debt obligations. Liquidity is supported by a current ratio of 2.52, indicating that the company holds more than twice the current assets necessary to cover its short-term liabilities, providing a buffer against immediate solvency risks. Return on Equity is -117.6% and Return on Assets is -48.7%, metrics that reveal that management is currently utilizing shareholder capital and assets to generate losses rather than returns, a common characteristic for biotech companies in the pre-revenue or pre-commercialization phase.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not applicable due to negative earnings, while the forward P/E is listed as -0.98, a metric that implies the market is pricing in continued losses or expects earnings to remain negative in the near term. The price-to-book ratio stands at 0.80, indicating that the company's market valuation is trading at a discount to its book value, which often reflects market skepticism regarding the near-term realization of its intangible assets or future revenue potential. Alternative valuation metrics such as the price-to-sales ratio of 2.32 and an EV/EBITDA of -0.26 suggest that investors are valuing the company primarily on its revenue generation capability rather than profitability, given that traditional earnings-based multiples are distorted by the net losses. The stock has traded within a 52-week range with a high of $4.98 and a low of $0.32, meaning the current valuation sits within this historical band but remains volatile. The beta value of 0.94 indicates that the stock's price volatility generally moves in line with the broader market, suggesting it does not exhibit significantly higher or lower systemic risk compared to a standard market index.
Growth & Income
Revenue growth year-over-year has declined by -63.4%, while earnings growth is not applicable due to the absence of prior period profitability, indicating that the company is currently shrinking in terms of top-line revenue rather than expanding. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute earnings to shareholders, implying that any retained earnings are theoretically available for reinvestment, though the current net loss suggests capital is being consumed rather than generated. The absence of a dividend yield confirms that the company's strategy involves retaining all available capital to fund its high-burn research and development activities rather than providing income to investors. Overall, the growth and income profile of CollPlant Biotechnologies is defined by significant revenue contraction and a complete lack of current profitability or income distribution, reflecting the high-risk, high-reward nature of its biotechnological business model.